- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03733925
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
December 27, 2022 updated by: Johnson & Johnson Private Limited
A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This post-marketing study will evaluate safety and efficacy profile of golimumab (a fully human anti-Tumour Necrosis Factor alpha [TNF-alpha] monoclonal antibodies [mAb], administered subcutaneously) in a real-world in Indian participants with active spondyloarthropathy of ankylosing spondylitis (AS) or psoriatic arthritis (PsA).
AS is a chronic inflammatory disease of unknown etiology that involves the sacroiliac joints, axial skeleton, entheses, and peripheral joints.
PsA is a chronic, inflammatory, usually rheumatoid factor negative arthritis that is associated with psoriasis.
Golimumab binds with high affinity to human TNF-alpha and inhibits TNF-alpha bioactivity, TNF-alpha-mediated cell cytotoxicity and TNF-alpha mediated endothelial cell activation.
Golimumab also induces activation of complement-mediated cell lysis and reduces the development of arthritis.
Study evaluation includes efficacy (efficacy parameters for AS and PsA) and safety.
Participant's safety will be monitored throughout the study.
The total duration of study will be approximately 24 weeks.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bangalore, India, 560079
- Chanre Rheumatology & Immunology Center & Research
-
Bhubaneswar, India, 751005
- Apollo Hospitals
-
Chennai, India, 600004
- Chennai Meenakshi Multispeciality Hospital
-
Hyderabad, India, 500082
- Nizams Institute of Medical Sciences NIMS
-
Kolkata, India, 700019
- Apollo Multispeciality Hospital Ltd
-
New Delhi, India, 110029
- All India Institute of Medical Sciences
-
New Delhi, India, 110060
- Sir Ganga Ram Hospital
-
New Delhi, India, 1100776
- Indraprastha Apollo Hospital
-
Pune, India, 411005
- Sancheti Institute for Orthopedics & Rehabilitation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
For participants with Ankylosing Spondylitis (AS):
- Have a diagnosis of definite AS (according to the Modified New York Criteria)
- Either has an inadequate response (defined as Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] greater than or equal to [>=]4) to current or past therapies (including biologics naïve participants). Participants who were receiving non-steroidal anti-inflammatory drugs (NSAIDs) or disease-modifying antirheumatic drugs (DMARDs) had to have received continuous therapy for 3 months at the highest recommended doses or had to have been unable to receive a full 3-month course of full-dose NSAID or DMARD therapy because of intolerance, toxicity, or contraindications. Maximum recommended dosages for DMARDs if used, would be: methotrexate 25 milligram per week (mg/week), oral corticosteroids (less than or equal to [<=]10 milligram per day [mg/day] of prednisone or equivalent) or sulfasalazine 3 gram per day (g/day)
For participants with Psoriatic Arthritis (PsA):
- Have PsA that was diagnosed at least 6 months prior to the first administration of study drug (according to the ClASsification criteria for Psoriatic ARthritis [CASPAR])
- Have at least 1 of the PsA subsets: Distal Interphalangeal (DIP) joint arthritis, polyarticular arthritis with the absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
- Are negative for rheumatoid factors according to the reference range of the local laboratory conducting the test
Exclusion Criteria:
- Are pregnant, nursing, or planning a pregnancy or fathering a child during the study or within 6 months after receiving the last administration of study drug
- Have a known hypersensitivity to human immunoglobulin proteins or other components of golimumab
- Have a history of latent or active granulomatous infection, including histoplasmosis, or coccidioidomycosis, prior to screening
- Have a chest radiograph within 3 months prior to the first administration of study drug that shows an abnormality suggestive of a malignancy or current active infection, including tuberculosis (TB)
- Have had a nontuberculous mycobacterial infection or opportunistic infection (for example, cytomegalovirus, pneumocystosis, aspergillosis) within 6 months prior to screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Golimumab
Participants will receive golimumab 50 milligram (mg) subcutaneous (SC) injection at Week 0 and every 4 weeks (q4w) thereafter through Week 24.
Concomitant medications may be allowed on a case by case basis as per the physician's judgement.
|
Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to Week 32
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product which does not necessarily have a causal relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product.
Any AE that occurred at or after the initial administration of study drug through the day of last dose plus 8 weeks was considered to be TEAE.
|
Up to Week 32
|
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs)
Time Frame: Up to Week 32
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product which does not necessarily have a causal relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product.
SAE was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.
Any AE that occurred at or after the initial administration of study drug through the day of last dose plus 8 weeks was considered to be TEAE.
|
Up to Week 32
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Ankylosing Spondylitis (AS) Participants With at Least 20 Percent (%) Improvement in the Assessment of SpondyloArthritis International Society (ASAS20) Criteria at Week 14
Time Frame: Week 14
|
ASAS 20 response criteria was defined as an improvement from baseline of greater than (>)20% and >1 unit in at least 3 of following 4 ASAS domains on scale of 0-10 units and no worsening from baseline of >20% and >1 unit in the remaining ASAS domain on a scale of 0-10 units.
The 4 ASAS domains were as follows (0-10 units numerical rating scale [NRS]): Patient's global assessment (PGA) of disease:0=not active spondylitis, 10=very active spondylitis; total and night Spinal pain: 0=no pain, 10=most severe pain; bath ankylosing spondylitis functional index (BASFI, self-assessment of participant's degree of mobility and functional ability represented as mean of 10 questions [8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life): 0=easy, 10=impossible; and bath ankylosing spondylitis disease activity index (BASDAI, self-assessment survey of 6 questions for participant's disability due to AS): 0=none, 10=very severe).
|
Week 14
|
Percentage of Psoriatic Arthritis (PsA) Participants Meeting the American College of Rheumatology 20% Improvement Criteria (ACR20) at Week 14
Time Frame: Week 14
|
ACR20 was is defined as greater than or equal to (>=) 20% improvement in swollen and tender joint count and >=20% improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS; 0-10 centimeter [cm], 0 cm=no pain and 10 cm=worst possible pain), PGA of disease activity by using VAS (the scale ranges from 0 cm to 10 cm, [0 cm=no pain to 10 cm=worst possible pain]), physician's global assessment of disease activity using VAS (scale ranges from 0 cm to 10 cm; [0 cm=very well and 10 cm=very poor]), participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas.
The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level.
|
Week 14
|
Percentage of AS Participants With ASAS20 Criteria at Week 24
Time Frame: Week 24
|
ASAS 20 response criteria was defined as an improvement from baseline of greater than (>) 20% and >1 unit in at least 3 of following 4 ASAS domains on scale of 0 to 10 units and no worsening from baseline of >20% and >1 unit in the remaining ASAS domain on a scale of 0 to 10 units.
The 4 ASAS domains were as follows (0 to 10 units NRS): PGA of disease:0=not active spondylitis, 10=very active spondylitis; total and night Spinal pain: 0=no pain, 10=most severe pain; BASFI, self-assessment of participant's degree of mobility and functional ability represented as mean of 10 questions [8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life): 0=easy, 10=impossible; and BASDAI, self-assessment survey of 6 questions for participant's disability due to AS): 0=none, 10=very severe).
|
Week 24
|
Percentage of PsA Participants Meeting the ACR20 Criteria at Week 24
Time Frame: Week 24
|
ACR20 was is defined as >=20% improvement in swollen and tender joint count and >=20% improvement in 3 of following 5 assessments: patient's assessment of pain using Visual Analog Scale (VAS; 0-10 centimeter [cm], 0 cm=no pain and 10 cm=worst possible pain), patient's global assessment of disease activity by using VAS (the scale ranges from 0 cm to 10 cm, [0 cm=no pain to 10 cm=worst possible pain]), PGA of disease activity using VAS (scale ranges from 0 cm to 10 cm; [0=very well and 10 cm=very poor]), participant's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas.
The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and ESR or CRP level.
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 7, 2019
Primary Completion (Actual)
November 15, 2021
Study Completion (Actual)
November 15, 2021
Study Registration Dates
First Submitted
November 5, 2018
First Submitted That Met QC Criteria
November 5, 2018
First Posted (Actual)
November 7, 2018
Study Record Updates
Last Update Posted (Actual)
January 20, 2023
Last Update Submitted That Met QC Criteria
December 27, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Joint Diseases
- Musculoskeletal Diseases
- Skin Diseases, Papulosquamous
- Spinal Diseases
- Bone Diseases
- Psoriasis
- Bone Diseases, Infectious
- Ankylosis
- Arthritis
- Arthritis, Psoriatic
- Spondylitis
- Spondylarthritis
- Spondylitis, Ankylosing
- Spondylarthropathies
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tumor Necrosis Factor Inhibitors
- Golimumab
Other Study ID Numbers
- CR108559
- CNTO148SPD4001 (Other Identifier: Johnson & Johnson Private Limited)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Psoriatic
-
AmgenRecruitingActive Juvenile Psoriatic ArthritisSpain, United Kingdom, Turkey, Belgium, France, Greece, Italy, Austria, Germany, Netherlands, Poland, Portugal, Romania, Lithuania, South Africa
-
Universitätsklinikum Hamburg-EppendorfBristol-Myers Squibb; Eli Lilly and Company; UCB Pharma; Merck Sharp & Dohme LLC; AbbVi... and other collaboratorsRecruiting
-
Sun Pharmaceutical Industries LimitedActive, not recruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Germany, India, Japan, Korea, Republic of, Poland, Spain
-
AbbVieActive, not recruitingPsoriatic Arthritis (PsA)United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
-
Sun Pharmaceutical Industries LimitedCompleted
-
Bristol-Myers SquibbCompletedActive Psoriatic ArthritisSpain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
-
Sun Pharmaceutical Industries LimitedRecruitingActive Psoriatic ArthritisUnited States, Australia, Czechia, Estonia, Korea, Republic of, Poland, Slovakia, Spain, Taiwan, Germany, Italy, India, Canada
-
Bristol-Myers SquibbCompletedPsoriatic Arthritis (PsA)Germany
-
Pope Research CorporationAmgenWithdrawn
-
Humanis Saglık Anonim SirketiCompletedPsoriasis and Psoriatic ArthritisIndia
Clinical Trials on Golimumab
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCCompletedColitis, UlcerativeUnited States, France, Poland, Ukraine, Germany, Belgium, Israel, Bulgaria, India, Romania, Serbia, South Africa, Japan, Canada, Australia, Netherlands, New Zealand, Russian Federation, Czech Republic, Hungary, Austria, Denmark, Lit... and more
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCCompletedColitis, UlcerativeUnited States, Canada, France, Poland, Ukraine, Germany, Israel, Bulgaria, India, Romania, Serbia, South Africa, Japan, Australia, Netherlands, Sweden, Belgium, New Zealand, Russian Federation, Czech Republic, Hungary, Austria, Denmark and more
-
Centocor, Inc.Schering-PloughCompletedArthritis, PsoriaticUnited States, Poland, United Kingdom, Spain, Canada, Belgium
-
Centocor, Inc.Schering-PloughCompletedSpondylitis, AnkylosingUnited States, Germany, Finland, Taiwan, Korea, Republic of, Canada, Belgium, Netherlands, France
-
Hospital de ManisesMerck Sharp & Dohme LLC; Hospital Arnau de Vilanova; Hospital Universitario La... and other collaboratorsUnknown
-
Alvotech Swiss AGActive, not recruitingRheumatoid ArthritisBulgaria
-
Janssen Research & Development, LLCMerck Sharp & Dohme LLCTerminatedColitis, UlcerativeUnited States, Poland, Germany, France, India, Romania, Serbia, Ukraine, Israel, Canada, Netherlands, Sweden, New Zealand, Russian Federation, Australia, Belgium, Hungary, Bulgaria, Slovakia, Latvia, Lithuania, Austria
-
Centocor, Inc.Schering-PloughCompletedArthritis, RheumatoidUnited States, Australia, United Kingdom, Germany, Spain, Canada, Finland, Austria, New Zealand, Netherlands
-
Centocor, Inc.CompletedHealthy VolunteersUnited States
-
Merck Sharp & Dohme LLCCompleted